Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
Saved in:
| Title: | Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181. |
|---|---|
| Authors: | Adenis A; Institut du Cancer de Montpellier and IRCM, Université Montpellier, Montpellier, France., Kulkarni AS; Merck & Co, Inc, Kenilworth, NJ., Girotto GC; Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil., de la Fouchardiere C; Centre Léon-Bérard, Lyon, France., Senellart H; Centre Rene Gauducheau ICO, Saint-Herblain, France., van Laarhoven HWM; Department of Medical Oncology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands., Mansoor W; Christie NHS Foundation Trust, Manchester, United Kingdom., Al-Rajabi R; University of Kansas Cancer Center, Kansas City, KS., Norquist J; Merck & Co, Inc, Kenilworth, NJ., Amonkar M; Merck & Co, Inc, Kenilworth, NJ., Suryawanshi S; Merck & Co, Inc, Kenilworth, NJ., Bhagia P; Merck & Co, Inc, Kenilworth, NJ., Metges JP; Centre Hospitalier Régional Universitaire de Brest-Hôpital Morvan, Arpego Network, Brest, France. |
| Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Feb 01; Vol. 40 (4), pp. 382-391. Date of Electronic Publication: 2021 Nov 03. |
| Publication Type: | Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1527-7755 |
|---|---|
| DOI: | 10.1200/JCO.21.00601 |
